Can ALX Break The CD47 Curse?

The company presented promising Phase II data at the ASCO-GI conference for evorpacept, a drug whose target has been problematic for other drug makers.

gastric cancer
• Source: Shutterstock

Phase II data for ALX Oncology’s evorpacept in gastric cancer raises the possibility that the company can succeed in an immunotherapy field that even some large drug companies have exited due to results that did not meet expectations.

The company presented data on 23 January at the American Society of Clinical Oncology Oncology’s Gastrointestinal Cancers Symposium from the...

More from Immuno-oncology

More from Scrip